Dosage forms useful for modifying conditions and functions associated with hearing loss and/or tinnitus
US6524619B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jan 19, 2001 |
| Grant date | Feb 25, 2003 |
| Priority date | — |
| Expiry date | Jan 19, 2021 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K33/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention defines interdependent biofactors and biomolecules, and clinically useful formulations that are comprised of them. The active agents are demonstrated to be complementary in their physiologic functions especially as these relate to the quenching of free radicals and to the support of endothelial physiology, the reduction of hyperinsulinemia and improvements in vascular health. The active components of the invention are selected for inclusion in precise combinations specifically because they improve these various conditions and physiological functions, and by so doing reduce a variety of risks associated with hearing loss and tinnitus. The resulting enhancement of general systemic vascular health, improvement in local VIIIth nerve vascular health, modulation of conditions surrounding blood fluid dynamics, the consequences of hyperinsulinemia, and improvements in free radical defenses, all reduce the potential for cochlear hair cell death and VIIIth nerve atrophy, and the hearing loss and possible deafness that accompany them.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.